European Journal of Dermatology
MENUPembrolizumab-associated mucous membrane pemphigoid during complete remission of metastatic non-small cell lung cancer Volume 32, issue 6, November-December 2022
Figures
1 Department of Dermatology and Venereology, Robert Debré Hospital, 51100 Reims, France
2 Jeanne de Navarre Hospital, 02400 Château-Thierry, France
3 Department of Pulmonary Medicine, Jeanne de Navarre Hospital, 02400 Château-Thierry France
4 Reims Champagne Ardenne University, IRMAIC, EA7509, 51100 Reims, France
- DOI : 10.1684/ejd.2022.4364
- Page(s) : 799-800
- Published in: 2022
Anti-programmed cell death protein-1 (PD-1) antibodies are immune checkpoints inhibitors (ICIs) used in the management of several types of malignancy that have considerably improved the prognosis of patients with advanced cancers [1]. However, these medications are associated with multiple immune-related adverse events (irAEs), of which 40% are cutaneous, consisting mainly of non-specific rashes, pruritus, and vitiligo [2]. Several cases of autoimmune bullous diseases (AIBD), mainly bullous pemphigoid [...]